cas 444289-05-8|| where to buy 3-[7-(aminomethyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride

Nom du produit:3-[7-(aminomethyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride

IUPAC Name:3-[4-(aminomethyl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione hydrochloride

: CAS：444289-05-8; Formule moléculaire：C14H16ClN3O3; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)
CM340808-100mg	in stock	ȡǶũ
CM340808-250mg	in stock	ŵǶǜ
CM340808-1g	in stock	ǜȡǜ
CM340808-5g	in stock	ŵŵŵũ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 444289-05-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:444289-05-8; Formule moléculaire:C14H16ClN3O3; Point de fusion:-; Code SMILES:O=C(C(N1CC2=C(C=CC=C2CN)C1=O)CC3)NC3=O.[H]Cl; Densité:

: Numéro de catalogue:CM340808; Poids moléculaire:309.75; Point d'ébullition:; N° Mdl:; Stockage:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.